Search This Blog

Monday, February 6, 2023

Biogen’s $1.5B Bet for Depressive Disorders Heads to FDA

 Biogen’s $1.5 billion bet is in the home stretch. On Monday, the Cambridge biotech, along with partner Sage Therapeuticsannounced the FDA has accepted the New Drug Application for zuranolone and granted it priority review in two mental health indications.

The NDA for zuranolone includes both Major Depressive Disorder (MDD) and Postpartum Depression (PPD), two indications with serious unmet needs.

Sage’s neuroactive steroid is designed as an episodic therapy. If approved, zuranolone would be the first 14-day treatment on the market for depression.

The rapid-acting, episodic nature of the drug is a differentiator for the depression market. With current treatments, patients are prescribed long-term treatments expecting efficacy 6-8 weeks in, Sage Chief Business Officer Chris Benecchi told BioSpace.

In addition to the delayed benefit, common side effects like weight gain and sexual dysfunction often “prevent patients from ultimately getting to the efficacy,” he said.

Biogen and Sage teamed up in late 2020 to jointly develop and commercialize zuranolone. A company representative said the NDA acceptance moves Biogen a step closer to “achieving [its] goal of changing how depression is thought about and treated."

In 2019, Sage announced zuranolone failed to hit its Phase III primary endpoint for MDD, not distinguishing itself from the placebo on the Hamilton Rating Scale for Depression (HAMD-17).

Jim Doherty, chief development officer at Sage, told BioSpace the “totality of the data is really strong.”

Because it’s not only a new drug but “potentially a very different way of thinking about treating depression,” the clinical program addressed a couple different questions, he said. Data across five other studies for MDD hit primary endpoints and showed a rapid improvement, as early as day three, after the second dose.

Zuranolone garnered more impressive results from its Phase III study in women with PPD. Utilizing HAMD-17, women on the drug saw a mean decrease of 15.6 points on the 17-item scale. Relief in anxiety symptoms appeared as early as day three on the drug and persisted through the 45-day follow-up.

With its priority review status, the FDA has assigned a Prescription Drug User Fee Act action date of Aug. 5.

The potential market for zuranolone is huge. Mental health disorders are among the leading causes of disability and disease burden worldwide, according to Global Burden of Disease’s research efforts.

PPD is one of the most common medical complications during and after pregnancy, affecting approximately one in eight women who have given birth.

Similarly, a 2020 survey estimated 14 million people in the U.S. have been diagnosed with major depressive disorder, with 190 million cases worldwide. These numbers were particularly high due to the global COVID-19 pandemic.

https://www.biospace.com/article/biogen-s-1-5b-bet-for-depressive-disorders-heads-to-fda/

Alcohol and dementia: Study finds benefits in minimal drinking, but it’s complicated

 Keeping alcohol consumption to one or two drinks a day lessened the odds of developing dementia, according to a study of nearly 4 million South Koreans.

However, drinking more than two drinks a day increased that risk, according to the study published Monday in the journal JAMA Network Open.

“We found that maintaining mild to moderate alcohol consumption as well as reducing alcohol consumption from a heavy to moderate level were associated with a decreased risk of dementia,” said first author Dr. Keun Hye Jeon, an assistant professor at CHA Gumi Medical Center, CHA University in Gumi, South Korea, in an email.

But don’t rush to the liquor store, experts say.

“This study was well done and is extremely robust with 4 million subjects, but we should be cautious not to over interpret the findings,” said Alzheimer’s researcher Dr. Richard Isaacson, a preventive neurologist at the Institute for Neurodegenerative Diseases of Florida. He was not involved in the new study.

Alcohol use can be a risk factor for breast and other cancers, and consuming too much can contribute to digestive problems, heart and liver disease, hypertension, stroke, and a weak immune system over time, according to the US Centers for Disease Control and Prevention.

There are red flags for Alzheimer’s as well. For example, if a person has one or two copies of the APOE4 gene variant, which raises your risk of developing the mind-wasting disease, drinking is not a good choice, Isaacson said.

“Alcohol has been shown to be harmful for brain outcomes in people with that risk gene — and about 25% of the US population carries one copy of APOE4,” he said.

Sizing up alcohol consumption

The new study examined the medical records of people covered by the Korean National Health Insurance Service (NHIS), which provides a free health exam twice a year to insured South Koreans who are 40 and older. In addition to doing various tests, examiners asked about each person’s drinking, smoking and exercise habits.

The study looked at the data collected in 2009 and 2011 and categorized people by their self-reported drinking levels. If a person said they drank less than 15 grams (approximately 0.5 ounces) of alcohol a day, they were considered “mild” drinkers.

In the United States, a standard drink contains 14 grams of alcohol, which is roughly the same as 12 ounces of regular beer, 5 ounces of wine or 1.5 ounces of distilled spirits.

If study participants told doctors they drank 15 to 29.9 grams a day — the equivalent of two standards drinks in the US — the researchers categorized them as “moderate” drinkers. And if people said they drank over 30 grams, or three or more drinks a day, researchers considered them “heavy” drinkers.

Researchers also looked at whether people sustained or changed the amount they drank between 2009 and 2011, Jeon said.

“By measuring alcohol consumption at two time points, we were able to study the relationship between reducing, ceasing, maintaining and increasing alcohol consumption and incident dementia,” he said.

The team then compared that data to medical records in 2018 — seven or eight years later — to see if anyone studied had been diagnosed with dementia.

After adjusting for age, sex, smoking, exercise level and other demographic factors, researchers found people who said they drank at a mild level over time — about a drink a day — were 21% less likely to develop dementia than people who never drank.

People who said they continued to drink at moderate level, or about two drinks a day, were 17% less likely to develop dementia, the study found.

“One has to be cautious when interpreting studies using medical records. They can be fraught with challenges in how diseases are coded and studied,” Isaacson said. “Any anytime you ask people to recall their behaviors, such as drinking, it leaves room for memory errors.”

Dangers of increasing drinking over time

The positive pattern did not continue as drinking increased. People who drank heavily — three or more drinks a day — were 8% more likely to be diagnosed with dementia, the study found.

If heavy drinkers reduced their drinking over time to a moderate level, their risk of being diagnosed with Alzheimer’s fell by 12%, and the risk of all-cause dementia fell by 8%.

However, people aren’t very good at judging how much alcohol they are drinking, Isaacson said.

“People don’t really monitor their pours of wine, for example,” Isaacson said. “They may think they are drinking a standard-sized glass of wine, but it’s really a glass and a half every time. Drink two of those pours and they’ve had three glasses of wine. That’s no longer mild or moderate consumption.”

In addition, too many people who think they are moderate drinkers do all of their drinking on weekends. Binge drinking is on the rise worldwide, even among adultsstudies show.

“If someone downs five drinks on Saturday and Sunday that’s 10 drinks a week so that would qualify as a moderate alcohol intake,” Isaacson said. “To me, that is not that is not the same as having a glass of wine five days a week with a meal, which slows consumption.”

The new study also found that starting to drink at a mild level was associated with a decreased risk of all-cause dementia and Alzheimer’s, “which, to our knowledge, has never been reported in previous studies,” the authors wrote.

However, “none of the existing health guidelines recommends starting alcohol drinking,” Jeon said, adding that since the study was observational, no cause and effect can be determined.

“Our findings regarding a initiation of mild alcohol consumption cannot be directly translated into clinical recommendations, thereby warranting additional studies to confirm these associations further,” Jeon said.

A study published in March 2022 found that just one pint of beer or glass of wine a day can shrink the overall volume of the brain, with the damage increasing as the number of daily drinks rises.

On average, people between 40 and 69 who drank a pint of beer or 6-ounce glass of wine per day for a month had brains that appeared two years older than those who only drank half of a beer, according to that previous study.

“I’ve never personally suggested someone to start drinking moderate amounts of alcohol if they were abstinent,” Isaacson said. “But there’s really not a one-size-fits-all approach towards counseling a patient on alcohol consumption.”

https://www.cnn.com/2023/02/06/health/alcohol-dementia-study-wellness/index.html

Covid convalescent plasma: the ‘little engine that could’

 The FDA’s withdrawal of its authorization for Evusheld, a monoclonal antibody therapy used to prevent and treat Covid-19, leaves no monoclonals available for this purpose. Another monoclonal, bebtelovimab, used to treat Covid-19, was withdrawn late last November. The FDA pulled its approval for these therapies because they were no longer effective against the newer SARS-CoV-2 variants circulating in the United States.

But an underused antibody alternative exists: Covid convalescent plasma (CCP). This is plasma rich in anti-Covid-19 antibodies that can be harvested from donors who have recently recovered from an infection. When used properly, it remains highly effective at reducing hospitalizations and death in people with Covid-19, and prevention studies in uninfected immunocompromised patients are being planned.

Unlike monoclonal antibodies, which can be defeated by new SARS-CoV-2 variants, CCP collected from vaccinated donors after recent breakthrough infections (VaxCCP) evolves with the variants and retains the ability to neutralize them. What makes CCP an even more promising therapy is that there are now many potential donors available in the U.S. who have been vaccinated and had recent breakthrough infections.

As with the once-effective monoclonal antibodies, CCP given to high-risk Covid-19-positive outpatients dramatically reduces the risk of hospitalization. Since studies supporting this use were conducted before the availability of VaxCCP, we believe that this more potent second-generation form of CCP will be even more effective than first generation used in 2020 and 2021.

Covid convalescent plasma given early in the course of hospitalization to less severely ill patients helps prevent deaths, something that was never demonstrated with monoclonal antibodies. We stress again that these observations were made with first-generation CCP, making it reasonable to imagine that the more potent second-generation will be at least as effective — or may be more effective — than first-generation CCP.

Immunocompromised people are especially vulnerable to SARS-CoV-2 infection. Many are unable to mount an antibody response to vaccination or infection. As a result, they are at high risk for poor outcomes, including death. Some immunocompromised people develop smoldering cases of Covid-19 that last for months or years. While their immune suppression apparently limits the risk of life-threatening pneumonia and acute respiratory distress syndrome, these lingering infections make these individuals veritable variant generators.

An array of data, including randomized controlled trials and careful retrospective studies, show a clear survival benefit when CCP is given to immunocompromised individuals who test positive for SARS-CoV-2. There are also impressive case reports and case series showing that Covid convalescent plasma, especially VaxCCP, is effective in patients with smoldering Covid-19.

So why isn’t CCP being more widely used? While the data on its effectiveness and appropriate use case is now clear three years into the pandemic, the path to clarity was long and twisted. Four important challenges emerged.

First, use of CCP at scale early in the pandemic was unexpected, as the Expanded Access Program designed to explore it grew beyond what anyone imagined when it started in April 2020. Even though data from the program showed a clear association between antibody dose, time to treatment, and survival, critics and evidence based medicine purists could always ask, “But where is data from the randomized controlled trial?” This concern was likely amplified by the rollout of data from the Expanded Access Program, including some confusion about the reduction in mortality communicated by then-FDA Commissioner Stephen Hahn at an August 2020 White House event immediately before the Republican National Convention, which politicized the therapy.

Second, the early “major” RCTs that tested the efficacy of CCP on survival in hospitalized patients tested the wrong use case. These studies treated patients who were too sick for too long to benefit from antibody therapy. But the major “negative” trials all showed evidence of effectiveness among people who received CCP earlier, who were not already desperately ill, who were immunocompromised, or who received the most antibodies. Unfortunately, these positive signals, which were consistent with impressive real-world data on Covid-19 and CCP, were buried under the top-line results.

Third, therapy is dominated by well-characterized small-molecule compounds with known pharmacologic characteristics that are given at fixed doses. They are embedded in treatment algorithms and decision trees. By contrast, blood products are far more variable than drugs and are typically titrated for each patient to some combination of physiological and biomarker-based endpoints. This variability, plus the limitations of the early trial results, may have limited enthusiasm for Covid convalescent plasma by some physicians, and also made it harder to incorporate into guidelines issued by professional societies and governmental agencies.

Such guidelines now dominate clinical practice in many large, consolidated health systems. Unfortunately, guidelines can be many months behind state-of-the-art data. For example, the WHO advised against using Covid convalescent plasma in December 2021 relying on data from the previous summer and has yet to update its guidance. These issues are especially acute during a fast-moving pandemic in an era when scientific communication has been accelerated via tools like preprints. Advocates for immunocompromised people believe that the lack of a full throated endorsement for CCP by the NIH Covid-19 guidelines panel has blunted enthusiasm and access to a potentially lifesaving therapy for them.

A fourth and final challenge has been the supply of Covid convalescent plasma in light of the confusion we have enumerated. The U.S. blood collection and banking system is a remarkable network of not-for-profit organizations. Early in the pandemic, the financial risk they took to collect and distribute CCP at scale was buffered by funding from the federal government. This funding was discontinued in 2021 and as a result, the collection and distribution of CCP declined rapidly during 2021.

With the loss of the remaining monoclonals from the anti-Covid armamentarium, immunocompromised people have no prophylactic options and will continue to need antibodies should they contract Covid-19. In this context, VaxCCP sufficient to treat between 500 and 1,000 immunocompromised people per week in the U.S. should be collected and distributed. (For context, through the Expanded Access Program and subsequent emergency use authorization, more than 500,000 units of Covid convalescent plasma were collected and delivered to hospitals large and small across the country.) Because the cost of CCP is modest compared to other treatment options — hundreds of dollars per unit of CCP compared to thousands per dose for monoclonals, even when purchased in bulk by the U.S. government — this would require only moderate subsidies to the U.S. blood collection and banking system. To standardize how CCP is used, guideline-making groups, including the National Institutes of Health, should partner with content experts to educate patients, physicians, and health systems about how to order and obtain VaxCCP. A prevention trial of VaxCCP in immunocompromised patients should also be initiated.

As the U.S. and the world enter the fourth year of the pandemic, Covid convalescent plasma is the “Little Engine That Could” of antibody therapy. With coordination and planning, we believe it should be poised to play a key role in the treatment of Covid-19 well into the future.

Michael J. Joyner is a professor in the Department of Anesthesiology and Perioperative Medicine at the Mayo Clinic and led the U.S. Expanded Access Program for Convalescent Plasma. Nigel Paneth is a professor emeritus of pediatrics and epidemiology at Michigan State University. Arturo Casadevall is chair of the Department of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health and chair of the National Covid-19 Convalescent Plasma Project. The views expressed here are those of the authors alone.

https://www.statnews.com/2023/02/06/covid-convalescent-plasma-antibody-therapy/

Why did EMS workers neglect Tyre Nichols?

 By the time medics arrived, Tyre Nichols was sitting on the ground, handcuffed and propped against a police car.

The 29-year-old’s face was bloody and he was groaning in pain. On Jan. 7, after pulling Nichols over for a traffic stop, Memphis police officers had tased him, pepper-sprayed him, punched him, kicked him in the head, and beaten him with a baton. He weighed about 150 pounds, according to his mother, and suffered from Crohn’s disease.

Other than helping Nichols back up when he slumped over, the emergency medical technicians  who’d arrived on the scene barely engaged with him, according to police body camera footage of the incident. As they stood nearby, Nichols collapsed onto the asphalt and writhed alone for minutes at a time.

National and state emergency medical services guidelines call for medics — at a bare minimum — to immediately check their patient’s airway, breathing, and vital signs. For head trauma, they would also immobilize the spine and neck, and give oxygen to prevent brain damage. None of that happened for Nichols. “They didn’t do bread and butter EMS,” said Ameera Haamid, an emergency medicine physician at the University of Chicago. “They didn’t do step one, which is, assess your patient.”

Even though they could have given him oxygen, administered intravenous treatment, and monitored his heart, the EMTs did nothing more clinical in the first 19 minutes they were on scene than shine a flashlight on Nichols. But all emergency clinicians are taught and trained that every minute matters in a medical crisis. “Their patient was in obvious distress,” said Sullivan Smith, a physician and member of Tennessee’s Emergency Medical Services Board. “It’s obvious to even a layperson that he was in terrible distress and needed help, and they failed to provide that help. They were his best shot. And they failed to help.”

Twenty-five minutes after police called for them to treat a pepper spray injury, a transport ambulance showed up to take Nichols to the hospital, where he died three days later.

In the wake of Nichols’ death, and with up to 20 more hours of body camera footage of Nichols’ beating and arrest still to be released, the public is scrutinizing not only the actions of police, but those of emergency clinicians. Following second-degree murder charges for six officers involved in the beating, the Memphis Fire Department also fired the two EMTs and their lieutenant for their “actions or inactions on the scene that night,” including a failure “to conduct an adequate patient assessment.” During an emergency meeting held Friday, Tennessee’s EMS board voted unanimously to revoke their licenses. Dennis Rowe, a board member and ambulance service operator, said there was “every reason to believe” that the EMTs’ inaction “may have contributed to the demise of that patient.”

Nichols, some say, is just the most recent example of EMS hesitating to administer appropriate aid to a severely injured Black man in police custody. “People are now starting to say, ‘Now wait a second, other people in uniform showed up too. What did they do? How did they act?” said Doug Wolfberg, a leading EMS industry lawyer and former EMT, and are “rightfully questioning the totality of this response by public safety.”

For Black communities, questions about whether they’d be cared for if they needed medical attention in a crisis are not new. “What does one have to do to be afforded the basic level of assessment?” said Italo Brown, an emergency physician at Stanford University and a health equity and social justice curriculum leader at its medical school. “Anywhere in America, if you’re in trouble, help will come. But if you’re a person of color, you have to think twice.”

Emergency clinicians, categorically, work in the eye of a crisis or in its direct wake.

They are often the first person to help someone on the worst day of their life — after a shooting, a building collapse, an attempted suicide, a car crash, a heart attack. Exposure to human suffering — to violence and trauma — is a routine and unavoidable fixture of the job. On highway shoulders, in shopping malls, and at strangers’ homes, in bad weather and around the clock and under immense time pressures, they handled 43.5 million medical calls in 2021 without the privilege of time, equipment, personnel, and training that’s afforded to hospital-based health care workers.

But in the U.S., EMS and law enforcement are also deeply intertwined. In a number of other high-profile police brutality cases — including the deaths of Elijah McClainGeorge Floyd, and Eric Garner, all of whom were Black — paramedics also have been scrutinized for their handling of someone in police custody. “The death of Tyre Nichols forces us to confront yet another moment where both those who have sworn to protect and those who have sworn to treat appear to have breached their duty,” wrote Donell Harvin, a homeland security and public health expert with EMS and law enforcement experience, in Politico.

Many EMS agencies operate out of the same jurisdiction as law enforcement agencies, which experts say leads to fraternization between police and emergency medics. That collegiality might make EMS personnel more likely to defer to the police, in part for fear that they’ll be perceived as obstructing justice by caring for someone who the police consider a suspect.

“They have a duty, I think, to directly declare to law enforcement this is a patient,” said Wolfberg, the EMS lawyer. But many EMS agencies and most states lack clear laws and guidelines on the point at which a detainment becomes a patient care setting, he said. Whether and how EMS can assume control of a law enforcement scene is, according to Wolfberg, “a very amorphous and potentially dangerous gray area.”

“They would have to ask the people with badges and guns to stand down,” he said.

Chris Ventura, an EMT, nationally certified EMS educator, and Johns Hopkins public health researcher, said it didn’t surprise him to see footage of EMTs’ apparent lack of empathy and action for Nichols. “I’ve seen it happen so many times,” Ventura said. “If it seems like we’re not treating someone as human, it’s because we’re not thinking of them as human.”

This can also be true in cases that don’t involve police brutality. Police footage from last December, for example, documented how paramedics treated Earl Moore Jr., a Black 35-year-old who was sick and hallucinating from alcohol withdrawal in Springfield, Ill. Police officers first responded to a call for help from someone in Moore’s home around 2 a.m. Once they saw the state he was in, they felt that Moore was in enough medical distress to call, in turn, for EMS.  Shortly after, a pair of paramedics entered his bedroom, where he was lying on the ground. “You know what, I am not playing. Sit up. Quit acting stupid. Sit up. Sit up now. I am not playing with you tonight,” one of the paramedics said. “You’re gonna have to walk cause we ain’t carrying you.”

Outside the home, body camera footage shows the other paramedic slamming Moore face-down on a stretcher; together, they pulled straps tight across his back. Court audio shows that during the ensuing three-and-a-half-minute ambulance ride, they refused to take Moore’s vital signs. He was pronounced dead at the emergency room. “They tied him down like some kind of animal and killed him,” Moore’s mother, Rose Washington, said of her only son. A coroner ruled Moore’s death a homicide by compressional and positional asphyxia, and the two paramedics now face first-degree murder charges.

Last August, in another Illinois incident, a first responder was fired after his patient stopped breathing while strapped to an ambulance stretcher, according to reporting by the Chicago Tribune. Police body camera footage shows medics didn’t assess Leonardo Guerrero, 44, despite the fact that he was found nude and intoxicated in a parking lot and was in a respiratory crisis. Strapped in and handcuffed to a stretcher, Guerrero “was lapsing in and out of consciousness” and gasping for air during the three-minute ambulance ride as paramedics ignored him. As his breathing slowed, paramedics “did not assess or care for the patient at all,” an official report said. Guerrero was pronounced dead in the emergency room, and his death was later ruled a homicide by the Cook County medical examiner’s office.

Guerrero’s loved ones, like Moore’s, say they believe paramedics discounted his care. “They just saw a homeless person in their eyes. They saw no value,” Guerrero’s sister told the Chicago Tribune.

Because emergency clinicians have to make split-second decisions, and because they depend on patterns and instincts to do so, they are also vulnerable to developing a reliance on stereotypes and unconscious biases, experts told STAT. They may, for example, be more likely to assume that an agitated unsheltered person is drunk or using drugs, rather than consider that they have low blood sugar or oxygen levels. When a patient is in police custody, EMS clinicians may be less likely to perceive the patient’s pain and injuries as genuine and instead attribute them to incarceritis, industry slang for exaggerating symptoms of illness or trauma in order to avoid jail.

In the past decade, research has begun to document how social factors such as gender, race, language, housing status, and income level can affect the quality and nature of emergency medical care. EMS is more likely to bring Black and Hispanic patients to hospitals that predominantly treat low-income and underserved patients, which often have lower quality of care, compared to white patients in the same geographic area. Black patients are 40% less likely to get pain medication than their white counterparts from emergency medical responders. Pulse oximeters, an essential EMS tool, overestimate oxygen levels in people with dark skin tones, making it less likely for emergency clinicians to detect a life-threatening need for oxygen.

The job’s working conditions can also make emergency clinicians more vulnerable to mistakes and biases.  EMS, as a profession, is a tough one to endure: The work is grueling, traumatizing, demeaning, and often thankless. Paramedics and EMTs make, on median, about $37,000 per year; approximately 1 in 10 do it for free as volunteers. Surveys suggest that most, if not all, are spit on, bitten, punched, stabbed, shot, or otherwise assaulted while earning that meager pay. “It cheese-graters your soul,” an EMT in Homer, Alaska, told STAT last year. Unsurprisingly, emergency clinicians routinely struggle with PTSD, suicide and suicidal thoughts, burnout, and job dissatisfaction; EMS agencies now experience a full staff turnover every three to four years, industry surveys show, with more than one-third of all new hires leaving within the first year of employment.

The field is also overwhelmingly white and male. In 2019, just 8% of EMTs and 5% of paramedics were Black, and about 13% were Hispanic. Research on LGBTQ personnel, scholars have noted, “is largely absent,” as are studies of the workforce’s socioeconomic status, language, religion, and ability.

It’s “very much an old boys club,” Sylvia Owusu-Ansah, the diversity and inclusion director of the National Association of EMS Physicians told STAT last year. “I’m pretty much on the national committee of every EMS organization that exists out there, and over 90% of the time, I’m one of the few women, I’m the only person of color, and I’m the youngest person.”

Steven Nelson, a Black, gay paramedic in Houston, has been called the n-word by patients and heard white co-workers use the slur. “If we are being honest here, I started to think people in this field were no different than some law enforcement officers I encountered,” Nelson wrote in 2021 about hearing colleagues voice negative stereotypes about Black people and show a lack of empathy and sympathy toward people of color in their care.

Taken together, the high-pressure, resource-limited nature of EMS work, the field’s lack of diversity, and the reality of both racism and unconscious biases can all work together to the detriment of marginalized patients, experts told STAT.  “The more burned out you are,” Haamid said, “the more heavily you are going to be relying on those biases.”

More broadly, the U.S. has a long, fraught history of medical apartheid in which marginalized communities, in particular Black people, have been sterilized, experimented on, exploited, and underserved by medicine. Experts told STAT that many vulnerable communities have been wary of calling 911 long before Nichols’ death. “It would be ridiculous for me to say that now this is going to make people suspicious,” Ventura said. “They already are.”

Haamid recently experienced firsthand the complications of calling 911 as a Black person.

Her dad, who has heart problems and is on blood thinners, was in severe abdominal pain. He couldn’t get down the stairs on his own. “I said, ‘Let me call 911, they’ll help you,’” said Haamid, who completed a fellowship in EMS after her training as an emergency physician.

Her father pushed back. He didn’t want his stomach pain to cost her a $1,000 ambulance ride. Haamid called anyway, even as he yelled at her not to. Once she realized the dispatcher heard yelling in the background, Haamid knew they’d send cops to check things out along with the ambulance.

Before she called 911, she’d wanted first responders to help her father out of the house. After the call, she wanted to get her father out of the house on her own, before police showed up and potentially endangered him further. “As a medical professional,” Haamid said, “I’m thinking, ‘Let’s get out of here before the police come.’”

https://www.statnews.com/2023/02/06/ems-tyre-nichols/